Results 11 to 20 of about 9,061 (176)

Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib [PDF]

Clinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo‐acute kidney injury. Creatinine–cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients.
Hiroaki Watanabe, Keita Hirai, Takaaki Oba, Mayu Ono, Ken‐ichi Ito, Takafumi Naito   +5 more
wiley   +2 more sources

The CDK4/6 inhibitor abemaciclib attenuates cognitive impairment and neuroinflammation via DYRK1A in human tau transgenic mice [PDF]

Molecular Brain
We recently demonstrated that abemaciclib treatment modulates cognitive function, Alzheimer's disease (AD) pathology, and neuroinflammatory responses in wild-type mice treated with lipopolysaccharide and in 5xFAD mice.
Hyun-ju Lee, Hyang-Sook Hoe
doaj   +2 more sources

Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer [PDF]

Медицинский совет, 2022
Introduction. Cyclin-dependent kinase 4/6 inhibitors are indicated in endocrine therapy for the treatment of hormone receptorpositive, HER2-negative, advanced, or metastatic breast cancer. In the recent past, abemaciclib made its debut as a combinatorial
A. Yu. Goryainova, A. I. Stukan, R. A. Murashko, S. V. Sharov, E. V. Lymar   +4 more
doaj   +2 more sources

Annona squamosa (custard apple) leaves extract mitigates abemaciclib-induced liver injury (AILI) in male rats

Arab Journal of Basic and Applied Sciences
Abemaciclib-induced liver injury (AILI) is a significant concern in clinical practice, since it may need dose reduction or withdrawal of abemaciclib and might impact following therapy options.
Lashin S. Ali, Gamal Mohamed, Ahmed A. El-Mansy, Khaled S. El-Bayoumi, Mohammed Y. Sobhey, Abd El-Fattah B. M. El-Beltagy, Reham A. Ghanem   +6 more
doaj   +2 more sources

The Real-world Experiences of Abemaciclib for Estrogen Receptor-positive Human Epidermal Growth Factor Receptor-negative-2 Metastatic Breast Cancer – Sharing from a Single Institute in Southern Taiwan

Journal of Cancer Research and Practice
Background: CDK 4/6 inhibitor (CDK4/6i) is the first-line therapeutic drug to treat ER-positive (ER+) HER2-negative (HER2 -) metastatic breast cancer (MBC) now. We have three CDK4/6i: Palbociclib, Ribociclib, and Abemaciclib.
Jui-Hung Tsai, Kuo-Ting Lee
doaj   +2 more sources

Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation [PDF]

Nature Communications, 2021
Abemaciclib is a third generation CDK-directed drug used in the treatment of HR + /HER2 negative advanced or metastatic breast cancer. Here the authors demonstrate that members of the Homeodomain-interacting protein kinases (HIPKs) HIPK3 and DYRK1A are ...
Ines H. Kaltheuner, Kanchan Anand, Jonas Moecking, Robert Düster, Jinhua Wang, Nathanael S. Gray, Matthias Geyer   +6 more
doaj   +2 more sources

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

npj Breast Cancer
In EMBER-3 (NCT04975308), among patients with ER + , HER2- advanced breast cancer (ABC) with recurrence/progression on/after endocrine therapy (ET), imlunestrant significantly prolonged PFS versus standard ET in patients with ESR1 mutations, and ...
Joyce O’Shaughnessy, Francois-Clement Bidard, Patrick Neven, Monica Lis Casalnuovo, Philippe Aftimos, Cristina Saura, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Jose A. Garcia-Saenz, Maria Fernandez Abad, Larissa de Paula, Yeon Hee Park, Ozgur Ozyilkan, Maria Munoz, Emily Barrett, Shanshan Cao, Aarti Chawla, Komal L. Jhaveri   +18 more
doaj   +2 more sources

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

npj Breast Cancer, 2021
In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer.
Stephen Johnston, Joyce O’Shaughnessy, Miguel Martin, Jens Huober, Masakazu Toi, Joohyuk Sohn, Valérie A. M. André, Holly R. Martin, Molly C. Hardebeck, Matthew P. Goetz   +9 more
doaj   +2 more sources

Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence [PDF]

Oncology and Therapy
Hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2–) breast cancer comprises approximately 70% of all breast cancer cases. In early-stage breast cancer, adjuvant endocrine therapy (ET) reduces recurrence and mortality, while ...
Miguel Martin, Alexandru Rosca, Alexandra Searles Vitko, Monique Coersmeyer, Katheryn Moreira, Huiping Li, Erica L. Mayer   +6 more
doaj   +2 more sources

Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition

Advanced Science
Alzheimer's disease (AD) is marked by progressive cognitive decline driven largely by tau pathology, yet disease‐modifying therapies targeting tau remain limited.
Jihui Han, June‐Hyun Jeong, Dongjoon Lee, Yujin Jung, Yujin Jin, Eun Sun Jung, Haeng Jun Kim, Woo Youn Kim, Chang‐Han Lee, Inhee Mook‐Jung   +9 more
doaj   +2 more sources